AngioDynamics Taps Medical Device Veteran Eric Honroth as CEO
Event summary
- Eric Honroth appointed President and CEO of AngioDynamics, effective November 2, 2026.
- Honroth succeeds Jim Clemmer, who will remain as a consultant for a smooth transition.
- Honroth brings 20+ years of medical device leadership experience, including roles at Abbott Vascular, Becton Dickinson, and Getinge.
- AngioDynamics highlights its high-growth Med Tech segment and strong balance sheet with no outstanding debt.
- Clemmer led the company through a decade-long transformation, focusing on sustainable growth and profitability.
The big picture
AngioDynamics' appointment of Eric Honroth as CEO underscores its focus on leveraging medical technology experience to drive sustainable growth. The move comes amid a broader industry trend of consolidating expertise in cardiovascular, endovascular, urology, and oncology sectors. With a strong balance sheet and high-growth Med Tech segment, the company aims to position itself for long-term value creation in a competitive healthcare landscape.
What we're watching
- Execution Risk
- Whether Honroth can sustain AngioDynamics' high-growth Med Tech segment and deliver on revenue and margin expansion promises.
- Strategic Alignment
- How Honroth's experience at Getinge and other medical device firms will translate to AngioDynamics' portfolio and growth priorities.
- Market Dynamics
- The pace at which AngioDynamics can capitalize on its strong balance sheet and no-debt position to drive long-term shareholder value.